New hope for hard-to-treat colorectal cancer: triple therapy enters phase 2 trial
Disease control
Recruiting now
This study tests a new oral drug (SR-8541A) combined with two immunotherapy drugs for people with a tough-to-treat type of colorectal cancer (MSS-CRC) that has spread and stopped responding to standard treatments. The goal is to find the best dose and see if the combination is sa…
Phase: PHASE2 • Sponsor: Stingray Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC